Method to enhance wound healing using silk-derived protein
Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.
1. A method for treating an ocular wound comprising:
applying a composition of silk fibroin-derived protein (SDP) fragments to living animal tissue in the ocular wound;
wherein a primary amino acid sequences of the SDP fragments differs from native silk fibroin by at least 4% with respect to the combined amino acid content of serine, glycine, and alanine;
the SDP fragments that have a serine content that is reduced by greater than 40% compared to native silk fibroin, wherein the serine content is at least about 5%;
wherein the SDP fragments are derived from silkworm silk, spider silk, or genetically engineered silk, and having an average molecular weight between about 30 kDa and 60 kDa, and
wherein a plurality of the SDP fragments terminate in amide (—C(═O)NH 2 ) groups, thereby treating the ocular wound.
2. The method of claim 1 , wherein cysteine disulfide bonds between the silk fibroin heavy and silk fibroin light protein chains of fibroin are reduced or eliminated.
3. The method of claim 1 , wherein the composition possesses enhanced stability in an aqueous solution compared to native silk fibroin.
4. The method of claim 1 , wherein the SDP protein fragments are derived from Bombyx mori.
5. The method of claim 1 , wherein at least 75 percent of the SDP fragments have a molecular weight of less than about 100 kDa.
6. The method of claim 1 , wherein at least 90 percent of the SDP fragments have a molecular weight of less than about 100 kDa.
7. The method of claim 1 , wherein at least 75 percent of the protein fragments have a molecular weight between about 30 kDa and 60 kDa.
8. The method of claim 1 , wherein at least 90 percent of the protein fragments have a molecular weight between about 30 kDa and 60 kDa.
9. The method of claim 1 , wherein at least 50 percent of the protein fragments have a molecular weight of greater than about 60 kDa.
10. The method of claim 1 , wherein the SDP fragments promote cell migration and proliferation in the tissue to close the wound.
11. The method of claim 1 , wherein the ocular wound is caused by an ocular condition, and wherein the ocular condition is corneal ulcer, corneal erosion, corneal abrasion, corneal degeneration, corneal perforation, corneal scarring, epithelial defect, keratoconjunctivitis, idiopathic uveitis, corneal transplantation, dry eye syndrome, age-related macular degeneration, diabetic eye, blepharitis, glaucoma, ocular hypertension, post-operative eye pain and inflammation, posterior segment neovascularization, proliferative vitreoretinopathy, cytomegalovirus retinitis, endophthalmitis, choroidal neovascular membrane, vascular occlusive disease, allergic eye disease, tumor, retinitis pigmentosa, eye infection, scleritis, ptosis, miosis, eye pain, mydriasis, neuralgia, cicatrizing ocular surface disease, ocular infection, inflammatory ocular disease, ocular surface disease, corneal disease, retinal disease, ocular manifestations of systemic diseases, hereditary eye condition, ocular tumor, increased intraocular pressure, herpetic infection, ptyrigium or scleral tumor, wound sustained to ocular surface, post-photorefractive keratotomy eye pain and inflammation, thermal or chemical burn to the cornea, scleral wound, or keratoconus and conjunctival wound.
12. The method of claim 1 , wherein the composition further comprises a pharmaceutical carrier and the composition is formulated as an aqueous solution, a suspension, a dispersion, a salve, an ointment, a gel, a cream, a lotion, a spray, or a paste.